Effectiveness of Thrombectomy in Stroke According to Baseline Prognostic Factors: Inverse Probability of Treatment Weighting Analysis of a Population-Based Registry.

Outcome Prognosis Propensity score Registries Stroke Thrombectomy

Journal

Journal of stroke
ISSN: 2287-6391
Titre abrégé: J Stroke
Pays: Korea (South)
ID NLM: 101602023

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 14 03 2021
accepted: 10 05 2021
entrez: 15 10 2021
pubmed: 16 10 2021
medline: 16 10 2021
Statut: ppublish

Résumé

 In real-world practice, the benefit of mechanical thrombectomy (MT) is uncertain in stroke patients with very favorable or poor prognostic profiles at baseline. We studied the effectiveness of MT versus medical treatment stratifying by different baseline prognostic factors.  Retrospective analysis of 2,588 patients with an ischemic stroke due to large vessel occlusion nested in the population-based registry of stroke code activations in Catalonia from January 2017 to June 2019. The effect of MT on good functional outcome (modified Rankin Score ≤2) and survival at 3 months was studied using inverse probability of treatment weighting (IPTW) analysis in three pre-defined baseline prognostic groups: poor (if pre-stroke disability, age >85 years, National Institutes of Health Stroke Scale [NIHSS] >25, time from onset >6 hours, Alberta Stroke Program Early CT Score <6, proximal vertebrobasilar occlusion, supratherapeutic international normalized ratio >3), good (if NIHSS <6 or distal occlusion, in the absence of poor prognostic factors), or reference (not meeting other groups' criteria).  Patients receiving MT (n=1,996, 77%) were younger, had less pre-stroke disability, and received systemic thrombolysis less frequently. These differences were balanced after the IPTW stratified by prognosis. MT was associated with good functional outcome in the reference (odds ratio [OR], 2.9; 95% confidence interval [CI], 2.0 to 4.4), and especially in the poor baseline prognostic stratum (OR, 3.9; 95% CI, 2.6 to 5.9), but not in the good prognostic stratum. MT was associated with survival only in the poor prognostic stratum (OR, 2.6; 95% CI, 2.0 to 3.3).  Despite their worse overall outcomes, the impact of thrombectomy over medical management was more substantial in patients with poorer baseline prognostic factors than patients with good prognostic factors.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
 In real-world practice, the benefit of mechanical thrombectomy (MT) is uncertain in stroke patients with very favorable or poor prognostic profiles at baseline. We studied the effectiveness of MT versus medical treatment stratifying by different baseline prognostic factors.
METHODS METHODS
 Retrospective analysis of 2,588 patients with an ischemic stroke due to large vessel occlusion nested in the population-based registry of stroke code activations in Catalonia from January 2017 to June 2019. The effect of MT on good functional outcome (modified Rankin Score ≤2) and survival at 3 months was studied using inverse probability of treatment weighting (IPTW) analysis in three pre-defined baseline prognostic groups: poor (if pre-stroke disability, age >85 years, National Institutes of Health Stroke Scale [NIHSS] >25, time from onset >6 hours, Alberta Stroke Program Early CT Score <6, proximal vertebrobasilar occlusion, supratherapeutic international normalized ratio >3), good (if NIHSS <6 or distal occlusion, in the absence of poor prognostic factors), or reference (not meeting other groups' criteria).
RESULTS RESULTS
 Patients receiving MT (n=1,996, 77%) were younger, had less pre-stroke disability, and received systemic thrombolysis less frequently. These differences were balanced after the IPTW stratified by prognosis. MT was associated with good functional outcome in the reference (odds ratio [OR], 2.9; 95% confidence interval [CI], 2.0 to 4.4), and especially in the poor baseline prognostic stratum (OR, 3.9; 95% CI, 2.6 to 5.9), but not in the good prognostic stratum. MT was associated with survival only in the poor prognostic stratum (OR, 2.6; 95% CI, 2.0 to 3.3).
CONCLUSIONS CONCLUSIONS
 Despite their worse overall outcomes, the impact of thrombectomy over medical management was more substantial in patients with poorer baseline prognostic factors than patients with good prognostic factors.

Identifiants

pubmed: 34649384
pii: jos.2021.00962
doi: 10.5853/jos.2021.00962
pmc: PMC8521260
doi:

Types de publication

Journal Article

Langues

eng

Pagination

401-410

Subventions

Organisme : Fondo de Investigacions Sanitarias of the Institut de Salud Carlos III to Ángel Chamorro and Xabier Urra
ID : FIS-ISCIII PI18/00444
Organisme : Fondo Europeo de Desarrollo Regional
Organisme : Instituto de Salud Carlos III
ID : INT19/00020
Organisme : European Social Fund
Organisme : Institute of Health Carlos III
ID : CM18/00116

Références

N Engl J Med. 2013 Mar 7;368(10):952-5
pubmed: 23394477
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Stroke. 2018 Oct;49(10):2398-2405
pubmed: 30355094
Stat Med. 2007 Dec 30;26(30):5586-95
pubmed: 17879268
J Clin Epidemiol. 2002 May;55(5):525-30
pubmed: 12007557
J Neurointerv Surg. 2019 Oct;11(10):989-993
pubmed: 30814327
Int J Stroke. 2008 May;3(2):130-7
pubmed: 18706007
Lancet Neurol. 2018 Oct;17(10):895-904
pubmed: 30264728
Neurology. 2020 Jul 14;95(2):e131-e139
pubmed: 32527972
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
Stroke. 2015 Dec;46(12):3437-42
pubmed: 26508752
JAMA Neurol. 2019 Oct 1;76(10):1147-1156
pubmed: 31355873
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
Clin Neuroradiol. 2020 Mar;30(1):43
pubmed: 32034461
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
J Neurointerv Surg. 2020 Feb;12(2):132-135
pubmed: 31273073
JAMA Neurol. 2020 Jan 1;77(1):16-24
pubmed: 31545353
N Engl J Med. 2013 Mar 7;368(10):893-903
pubmed: 23390923
Stroke. 2019 Apr;50(4):880-888
pubmed: 30827193
Lancet. 1998 Oct 17;352(9136):1245-51
pubmed: 9788453
Cerebrovasc Dis. 2014;38(6):418-24
pubmed: 25472576

Auteurs

Salvatore Rudilosso (S)

Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.
Clinical and Experimental Neuroscience: Cerebrovascular Diseases, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.

José Ríos (J)

Medical Statistics Core Facility, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Hospital Clinic, Barcelona, Spain.
Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain.

Alejandro Rodríguez (A)

Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.

Meritxell Gomis (M)

Stroke Unit, Department of Neuroscience, Germans Trias Hospital, Badalona, Spain.

Víctor Vera (V)

Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.

Manuel Gómez-Choco (M)

Department of Neurology, Moisès-Broggi Hospital, Sant Joan Despí, Spain.

Arturo Renú (A)

Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.
Clinical and Experimental Neuroscience: Cerebrovascular Diseases, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.

Núria Matos (N)

Department of Neurology, Althaia Foundation Hospital, Manresa, Spain.

Laura Llull (L)

Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.
Clinical and Experimental Neuroscience: Cerebrovascular Diseases, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.

Francisco Purroy (F)

Stroke Unit, Department of Neurology, University Hospital Arnau of Vilanova, Lleida, Spain.

Sergio Amaro (S)

Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.
Clinical and Experimental Neuroscience: Cerebrovascular Diseases, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.

Mikel Terceño (M)

Stroke Unit, Department of Neurology, Josep Trueta University Hospital, Girona, Spain.

Víctor Obach (V)

Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.

Joaquim Serena (J)

Stroke Unit, Department of Neurology, Josep Trueta University Hospital, Girona, Spain.

Joan Martí-Fàbregas (J)

Stroke Unit, Department of Neurology, Santa Creu i Sant Pau, Barcelona, Spain.

Pedro Cardona (P)

Stroke Unit, Department of Neurology, Bellvitge University Hospital, Barcelona, Spain.

Carlos Molina (C)

Stroke Unit, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain.

Ana Rodríguez-Campello (A)

Stroke Unit, Department of Neurology, Hospital del Mar, Barcelona, Spain.

David Cánovas (D)

Department of Neurology, Parc Taulí Hospital, Sabadell, Spain.

Jerzy Krupinski (J)

Department of Neurology, Mutua de Terrassa University Hospital, Terrassa, Spain.

Xavier Ustrell (X)

Stroke Unit, Department of Neurology, Joan XXIII University Hospital, Terragona, Spain.

Ferran Torres (F)

Medical Statistics Core Facility, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Hospital Clinic, Barcelona, Spain.
Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain.

Luis San Román (LS)

Department of Radiology, Hospital Clínic of Barcelona, Barcelona, Spain.

Mercè Salvat-Plana (M)

Department of Health, Pla Director Malaltia Vascular Cerebral (Catalan Stroke Program), Barcelona, Spain.

Francesc Xavier Jiménez-Fàbrega (FX)

Emergency Medical Services of Catalonia, Barcelona, Spain.

Ernest Palomeras (E)

Department of Neurology, Hospital of Mataró, Mataró, Spain.

Esther Catena (E)

Department of Neurology, Consorci Sanitari Garraf Hospital, Sant Pere de Ribes, Spain.

Carla Colom (C)

Department of Emergency, Hospital of Igualada, Igualada, Spain.

Dolores Cocho (D)

Department of Emergency, Hospital of Granollers, Granollers, Spain.

Juanjo Baiges (J)

Department of Emergency, Verge de la Cinta Hospital, Tortosa, Spain.

Josep Maria Aragones (JM)

Department of Emergency, Vic University Hospital, Vic, Spain.

Gloria Diaz (G)

Department of Emergency, Hospital of Campdevànol, Campdevànol, Spain.

Xavier Costa (X)

Department of Emergency, Hospital of Figueres, Figueres, Spain.

María Cruz Almendros (MC)

Department of Emergency, Hospital of Palamós, Palamós, Spain.

Maria Rybyeba (M)

Department of Emergency, Hospital of Olot, Olot, Spain.

Miquel Barceló (M)

Department of Emergency, Cerdanya Hospital, Puigcerdá, Spain.

Dolors Carrión (D)

Department of Emergency, Hospital of Móra d'Ebre, Móra d'Ebre, Spain.

Matilde Núria Lòpez (MN)

Department of Emergency, Seu d'Urgell Hospital, Seu d'Urgell, Spain.

Eduard Sanjurjo (E)

Department of Emergency, Hospital of Tremp, Tremp, Spain.

Natalia Pérez de la Ossa (NP)

Stroke Unit, Department of Neuroscience, Germans Trias Hospital, Badalona, Spain.
Department of Health, Pla Director Malaltia Vascular Cerebral (Catalan Stroke Program), Barcelona, Spain.

Xabier Urra (X)

Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.
Clinical and Experimental Neuroscience: Cerebrovascular Diseases, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.

Ángel Chamorro (Á)

Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.
Clinical and Experimental Neuroscience: Cerebrovascular Diseases, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
University of Barcelona, Barcelona, Spain.
Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic of Barcelona, Barcelona, Spain.

Classifications MeSH